Mon, Jul 28, 2014, 9:18 AM EDT - U.S. Markets open in 12 mins.


% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mtdsus mtdsus Oct 15, 2012 9:46 AM Flag

    Amarin Quiet Period not "self imposed"; it's a legal requirement EOM

    Amylin CEO remained quiet after Bloomberg reported a bid for 22$/share in April,2012.
    Even Ichan-a big shareholder/Director could not get CEO to divulge if the bid by BMY was true? So Ichan decided to sue Amylin--and asked him to hire Financial advisors to SELL the Co.
    Finally CEO and Ichan settled out of court--after CEO agreed to hire Goldman Sachs and Openheimer in May.
    Goldman Sachs tried to move the bid from 22 to 35$. But it got stuck at 28$/share after second round of bidding. Finally Goldman found Astra Zeneca-who agreed to share the deal with BMY and each paid 3.5bil.$-for a total of 7 bil.$.BMY has the rights in USA--and AZN for outside USA. In April,Bloomberg asked AZN-Director of Business Develop.--Will you buy Amylin or Amarin--after he said--AZN is focussing on Cancer(Ardea purchase),Diabeties,and Gastrointestinal medicines(as Nexium patents expire in 2014.). The Director of Bus.Develop. did not reply--but did buy Amylin after GS pursuation. I asked this Director--about Amarin buy 2 months ago.He said--we have spent 5 bil.$ already for Ardea and Amylin. Let's see if new CEO--who has stopped buyback of AZN shares thus saving 2 bil.$ in cash--is willing to buy Amarin.
    My guess--based on 2 competent sources(whose guesses are better than mine)--is that GSK and Pfizer are interested--whether they will pay 30$/share-- could derail the buyout. GSK is comfortable with under 25$/share.
    We will find out by Nov.16th.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.50Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.